Kyntra Bio公布FG-3246联合恩杂鲁胺治疗转移性去势抵抗性前列腺癌的研究者发起1B/2期研究积极数据,将于2026年ASCO GU大会展示

美股速递
Feb 24

Kyntra Bio公司宣布,其FG-3246与恩杂鲁胺联合用药方案针对转移性去势抵抗性前列腺癌患者的临床研究取得积极进展。这项由研究者发起的1B/2期试验数据显示出显著治疗潜力,相关完整数据报告已获选将于2026年美国临床肿瘤学会泌尿生殖系统肿瘤研讨会进行正式发布。

该研究聚焦于晚期前列腺癌治疗领域的前沿探索,通过双药联用策略旨在突破现有治疗方案瓶颈。试验结果不仅验证了联合用药的安全性特征,更展现出令人鼓舞的疗效信号,为转移性去势抵抗性前列腺癌患者提供了新的治疗希望。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10